Alterity Therapeutics Limited

NasdaqCM:ATHE 株式レポート

時価総額:US$10.5m

Alterity Therapeutics 過去の業績

過去 基準チェック /06

Alterity Therapeutics's earnings have been declining at an average annual rate of -2.6%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 9% per year.

主要情報

-2.6%

収益成長率

31.6%

EPS成長率

Biotechs 業界の成長17.0%
収益成長率9.0%
株主資本利益率-138.6%
ネット・マージン-475.8%
前回の決算情報30 Jun 2024

最近の業績更新

Recent updates

Alterity launches phase 2 study of ATH434 for multiple system atrophy in UK

Aug 25

Alterity begins dosing in mid-stage study of ATH434 for multiple system atrophy

Jul 06

Alterity: The Alternate Prana With New U.S. Patents In Iron Chaperone Technology

Sep 16

Alterity Therapeutics names Dr. David Stamler as CEO

Jan 07

Alterity and UniQuest partner to reverse bacterial resistance to antibiotics

Dec 21

Alterity Therapeutics nabs US patent for compounds for neurodegenerative disorders

Nov 16

収支内訳

Alterity Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqCM:ATHE 収益、費用、利益 ( )AUD Millions
日付収益収益G+A経費研究開発費
30 Jun 244-19519
31 Mar 244-16515
31 Dec 233-12412
30 Sep 234-13512
30 Jun 234-14513
31 Mar 235-14514
31 Dec 225-14516
30 Sep 225-14515
30 Jun 225-13615
31 Mar 225-13514
31 Dec 215-13713
30 Sep 215-14813
30 Jun 214-15712
31 Mar 212-16711
31 Dec 200-16510
30 Sep 200-15410
30 Jun 200-13310
31 Mar 202-13411
31 Dec 194-13413
30 Sep 195-12413
30 Jun 195-12413
31 Mar 195-11412
31 Dec 184-10410
30 Sep 184-948
30 Jun 183-847
31 Mar 183-845
31 Dec 173-844
30 Sep 173-845
30 Jun 173-846
31 Mar 174-847
31 Dec 164-948
30 Sep 164-849
30 Jun 165-8410
31 Mar 165-8411
31 Dec 156-7512
30 Sep 156-7512
30 Jun 156-6512
31 Mar 158-6613
31 Dec 1410-7313
30 Sep 149-10314
30 Jun 148-13515
31 Mar 146-12313
31 Dec 134-11311

質の高い収益: ATHE is currently unprofitable.

利益率の向上: ATHE is currently unprofitable.


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: ATHE is unprofitable, and losses have increased over the past 5 years at a rate of 2.6% per year.

成長の加速: Unable to compare ATHE's earnings growth over the past year to its 5-year average as it is currently unprofitable

収益対業界: ATHE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


株主資本利益率

高いROE: ATHE has a negative Return on Equity (-138.6%), as it is currently unprofitable.


総資産利益率


使用総資本利益率


過去の好業績企業の発掘